Trial Profile
A Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Study to Evaluate the Safety and Efficacy of Huperzine A Sustained-Release Tablets in Patients With Mild to Moderate Alzheimer's Disease.
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Huperzine A (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 02 Feb 2011 New trial record